Cost Effectiveness Analysis Heparin dan Enoxaparin Dalam Terapi Coronavirus Disease 19
Andy Kurniawan Saputra, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS; dr. Ika Trisnawati, M.Sc, Sp.PD, KP2023 | Tesis | S2 Mag.Farmasi Klinik
Hypercoagulation is a condition characterized by increased thrombosis and is caused by various factors, one of which is COVID-19. Anticoagulants are the main therapeutic options such as heparin and enoxaparin. The administration of these two drugs can reduce coagulation parameters such as D-dimer, prothrombin time, and fibrinogen. The purpose of this study was to analyze the cost-effectiveness comparison of heparin and enoxaparin as anticoagulants in severe and critical COVID-19 patients.
This study is an analytical observational study with a retrospective cohort design from a provider perspective. The research subjects were severe and critical COVID-19 patients who met the inclusion and exclusion criteria at Dr. Sardjito General Hospital in the period January 2021 - January 2022. The effectiveness of anticoagulants was seen through a decrease in the D-dimer to < 500>
The achievement of D-dimer value < 500 p=0.293)>
Kata Kunci : antikoagulan, cost-effectiveness, enoxaparin, heparin, COVID-19